The cardiovascular space has witnessed a surge in strategic collaborations and licensing deals as companies race to address the rising global burden of heart disease with next-generation therapies. Recent transactions reflect a sharpened focus on precision cardiology, novel protein targets, and RNA-based approaches, underscoring the industry’s shift toward innovation-driven growth. These alliances not only aim to bolster R&D pipelines but also signal a broader trend of de-risking early assets through shared expertise and capital.
ProFound Therapeutics and Novartis Enter Strategic USD 750 million Collaboration to Advance Novel Cardiovascular Therapies Usin...
